Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Silicone, DLC, sol-gel ceramics, bio-based polymers, and plasma films mapped against PFAS performance benchmarks and 2025–2027 regulatory deadlines.
Article | Rapport How to design high-entropy alloy compositions with simultaneous high strength and ductility—covering ML-driven screening, CALPHAD phase prediction, and thermomechanical processing.
Article | Rapport China controls ~90% of rare earth processing and ~85% of NdFeB magnet output. Discover how export controls, cerium alternatives, and Western capacity buildouts are reshaping the global magnet supply chain.
Article | Rapport How to engineer LFP cathode composition and particle morphology to simultaneously improve cycle life, rate performance, and thermal stability for EV batteries.
Article | Rapport How do Sacituzumab Govitecan, Datopotamab Deruxtecan, and Trastuzumab Deruxtecan differ in TNBC? A deep-dive into target biology, bystander killing, and resistance.
Article | Rapport Thermo Fisher leads mass spectrometry with 341 patents; Danaher counters with 377 across subsidiaries. Explore divergent R&D strategies shaping life science instruments 2015–2026.
Article | Rapport Bimekizumab vs secukinumab: head-to-head trial data, patent evidence, and mechanistic rationale for dual IL-17A/F blockade across psoriasis, axSpA, and HS.
Article | Rapport How selective androgen receptor degraders (SARDs) use the ubiquitin-proteasome system to overcome LBD mutations and AR-V7 splice variants driving mCRPC resistance.
Article | Rapport Deep analysis of Novartis patent WO2015009616A1: Iptacopan Factor B inhibitor binding pocket interactions, selectivity SAR, ADME/PK, and piperidine vs pyrrolidine scaffold comparison.
Article | Rapport LK-99 debunked, hydride systems hitting 556K, and zero ambient-pressure candidates validated. The room-temperature superconductor landscape in 2026, fully mapped.
Article | Rapport Patent CN115485277B reveals Zongertinib's 133× HER2/EGFR selectivity, cysteine engagement strategy, and 19 lead compounds with sub-nanomolar IC50 values.
Article | Rapport CagriSema (amylin/GLP-1) vs. Tirzepatide (GIP/GLP-1): mechanistic differences, clinical trial data, weight loss outcomes, and cardiometabolic profiles compared.
Article | Rapport How Micron's 621 HBM patents and SK Hynix's 50% market share define the HBM2E-to-HBM4 race. Deep-dive patent strategy, DRAM architecture, and 2026 outlook.
Article | Rapport Deep analysis of WO2019044947A1: T-DXd GGFG linker chemistry, DXd payload conjugation, DAR 7-8 optimization, and how these structural innovations widen the therapeutic index vs. T-DM1.
Article | Rapport How CNS-penetrant BTK inhibitors tolebrutinib and fenebrutinib target smoldering neuroinflammation differently from anti-CD20 therapies in MS.